Skip to content

Effect of Traditional Chinese Medicine of Severe COVID-19

Integrated Traditional Chinese and Conventional Medicine in Treatment for Patients with Severe COVID-19: Study Protocol for a Randomized Controlled Trial

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06714032
Acronym
COVID-19
Enrollment
172
Registered
2024-12-03
Start date
2023-01-29
Completion date
2024-01-25
Last updated
2024-12-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Severe COVID-19

Keywords

Traditional Chinese Medicine, Severe COVID-19

Brief summary

This study evaluated the effect of integrated traditional Chinese and Western medicine in the treatment of Severe COVID-19. The patients were randomly divided into experimental group and control group.

Detailed description

In this study, a multi center randomized controlled trial design was adopted, and the subjects were randomly divided into the experimental group and the control group. The control group was treated with western medicine conventional treatment plus traditional Chinese medicine decoction simulant, while the experimental group was treated with traditional Chinese medicine syndrome differentiation treatment decoction. The course of treatment was 14 days and the patients were followed up for 3 months. The clinical effect of integrated traditional Chinese and Western medicine treatment was evaluated from the aspects of 28 day mortality, 28 days without invasive mechanical ventilation, invasive mechanical ventilation rate, 28 days without ICU stay, clinical stability time, length of hospital stay, quality of life, SOFA score, etc., to clarify the clinical efficacy of integrated traditional Chinese and Western medicine treatment for Severe COVID-19 infection.

Interventions

All patients were treated according to international guidelines. The Experimental group will receive TCM according to the TCM syndrome.

All patients were treated according to international guidelines. The control group will receive TCM placebo according to the TCM syndrome.

Sponsors

Henan University of Traditional Chinese Medicine
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* accord with the diagnosis of severe/critical novel coronavirus infection; * Age \> 18 years old; * TCM syndrome differentiation diagnosis by the attending physician or above or two attending physicians for diagnosis and consensus; * Sign the informed consent form.

Exclusion criteria

* Pregnant and lactating women; * Trauma, hematological malignancies, various solid tumors and obstetric complications; * Dementia, various mental patients and those who are unwilling to cooperate; * The patient is expected to die within the next 24 hours; * Combined with neuromuscular diseases affecting respiratory and motor functions; * people who have been bedridden for a long time for various reasons; * Clinical trial participants who are taking part in other intervention measures; * Those who are known to be allergic to the therapeutic drugs in this study.

Design outcomes

Primary

MeasureTime frameDescription
28-day mortalityMortality on the 28th day of treatmentProportion of patients who died of disease on day 28

Secondary

MeasureTime frameDescription
invasive mechanical ventilation rate28 days in the treatment phaseRate of patients receiving invasive mechanical ventilation
days of non-ICU28 days in the treatment phaseCalculate the number of days of patients not staying in ICU within 28 days
time to clinical stabilityevery day in the treatment.temperature of 37.2°C orlower, heart rate of 100 beats/min or lower, systolic blood pressure of 90 mm Hg or higher, and arterial oxygen tension of 60 mm Hg or higher when the patient was not receiving supplemental oxygen.
hospitalization timethe 28 days of the treatment phaselength of hospital stays will be recorded.
Days without invasive mechanical ventilationthe 28 days of the treatment phaseDays without invasive mechanical ventilation in 28 days
Quality of lifeThe scores on the 1st, 4th, 7th, 14th, 21st and 28th day of admission were counted.Score according to the quality of life table,the minimum score is 12 points, and the maximum score is 60 points. The higher the score, the worse the result.
TCM syndrome scoreThe scores on the 1st, 4th, 7th, 14th, 21st and 28th day of admission were counted.Traditional Chinese Medicine Syndrome Points.Including cough, expectoration, dyspnea, chest pain, anorexia and fatigue, each item is rated as 1-5 points from mild to severe.The minimum score is 6 points and the maximum score is 30 points. The higher the score, the worse the result.
SOFA scoreThe scores on the 1st, 4th, 7th, 14th, 21st and 28th day of admission were countedSequential Organ Failure Assessment.It is a scoring system for evaluating and monitoring the organ function of critically ill patients.The minimum score is 0 and the maximum is 24. The higher the score, the worse the result.
Clinical status of patients 15 days after randomizationThe clinical status of patients was observed 15 days after randomization.According to the 6-point clinical improvement scale of the World Health Organization, the lowest score was 1 and the highest was 6. The higher the score, the worse the result.

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026